The Applied Molecular Pathology Laboratory (AMPL) has been in development during fiscal year 2010, with the hiring of two staff members, acquisition of capital equipment and development of standard operating procedures, with the initiation of studies to commence in FY 2011. During the start up phase, standard operating procedures for construction of tissue microarrays (TMAs), validated immunohistochemistry, and the isolation of RNA and DNA from formalin fixed paraffin embedded tissue have been developed. A digital image database has been implemented for the organization and collection of annotations and outputs of image analysis of digital pathology images.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Scientific Cores Intramural Research (ZIC)
Project #
1ZICBC011257-04
Application #
8763769
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2013
Total Cost
$219,948
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Camargo, M Constanza; Kim, Woo-Ho; Chiaravalli, Anna Maria et al. (2014) Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. Gut 63:236-43
Li, Wen-Qing; Hu, Nan; Burton, Victoria H et al. (2014) PLCE1 mRNA and protein expression and survival of patients with esophageal squamous cell carcinoma and gastric adenocarcinoma. Cancer Epidemiol Biomarkers Prev 23:1579-88
Jia, Jinping; Bosley, Allen D; Thompson, Abbey et al. (2014) CLPTM1L promotes growth and enhances aneuploidy in pancreatic cancer cells. Cancer Res 74:2785-95
Horne, Hisani N; Sherman, Mark E; Garcia-Closas, Montserrat et al. (2014) Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression. Breast Cancer Res Treat 143:181-7
Yang, Xiaohong R; Figueroa, Jonine D; Hewitt, Stephen M et al. (2013) Estrogen receptor and progesterone receptor expression in normal terminal duct lobular units surrounding invasive breast cancer. Breast Cancer Res Treat 137:837-47